Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of “Hold” by Brokerages

Rein Therapeutics Inc. (NASDAQ:RNTX) has been given an average rating of “Hold” by the four research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $6.00.

A number of equities research analysts recently issued reports on the company. HC Wainwright lowered their price objective on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Maxim Group assumed coverage on shares of Rein Therapeutics in a research note on Monday, July 20th. They issued a “buy” rating and a $4.00 target price for the company. Wall Street Zen raised shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings upgraded shares of Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 3rd.

Institutional Investors Weigh In On Rein Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sigma Planning Corp boosted its holdings in shares of Rein Therapeutics by 41.0% in the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock worth $453,000 after acquiring an additional 101,400 shares during the period. Chicago Partners Investment Group LLC boosted its stake in Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after purchasing an additional 10,000 shares during the period. State Street Corp grew its holdings in Rein Therapeutics by 374.3% during the 4th quarter. State Street Corp now owns 75,904 shares of the company’s stock valued at $88,000 after buying an additional 59,900 shares in the last quarter. Voss Capital LP grew its holdings in Rein Therapeutics by 59.2% during the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock valued at $4,923,000 after buying an additional 1,577,437 shares in the last quarter. Finally, Gagnon Securities LLC grew its holdings in Rein Therapeutics by 5.0% during the 4th quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock valued at $279,000 after buying an additional 11,528 shares in the last quarter. Institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Trading Down 2.2%

Shares of NASDAQ RNTX opened at $0.79 on Friday. The stock has a fifty day simple moving average of $0.89 and a two-hundred day simple moving average of $1.14. Rein Therapeutics has a 1-year low of $0.69 and a 1-year high of $2.18. The firm has a market cap of $67.36 million, a price-to-earnings ratio of -0.41 and a beta of 1.39.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30. Analysts forecast that Rein Therapeutics will post -0.53 EPS for the current year.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.